Masimo Corporation (MASI - Free Report) recently announced that its SET Measure-through Motion and Low Perfusion pulse oximetry might be a useful initial screening method to identify children with Down Syndrome (DS) who are at a high risk of obstructive sleep apnea (OSA).
Out of 161 children with DS, 25 were separately diagnosed with OSA having monitored overnight using Masimo Radical-7 Pulse CO-Oximeters.
Notably, the screening method might replace multichannel sleep studies, which are expensive and also available at specialist centers.
For investors’ notice, in the recently-reported second quarter of 2018, Masimo shipped a whopping 58,700 oximeters and brain function monitors, which drove overall earnings.
Global Prospects
Per research by MarketsandMarkets, the sleep apnea devices market is projected to reach a worth of $6.49 billion by 2023 from an estimated $4.44 billion in 2018, at a CAGR of 7.8%. Increase in the incidence of lifestyle diseases like obesity and government efforts to spread awareness regarding sleep apnea propel growth.
Hence the latest development has been a well-timed one for Masimo.
Sleep Apnea in US
A research by the U.S. National Library of Medicine shows that OSA is a frequent occurrence during childhood, with a median incidence of about 10% among preschool and school-aged children.
MedTech bigwig ResMed Inc. (RMD - Free Report) is one of the key players in the sleep apnea devices market. The company offers devices like AirSense 10 Elite, AirSense 10 AutoSet and AirCurve 10 CS PaceWave which deserve a special mention here.
Meanwhile, the Zacks Consensus Estimate for the company’s current-year earnings is pegged at $2.90, reflecting growth of 18.4% from last year.
We believe developments such as these will help Masimo survive cutthroat competition from bigwigs like Intuitive Surgical (ISRG - Free Report) and Inogen, Inc. (INGN - Free Report) . Intuitive Surgical’s robot-based da Vinci surgical system enables minimally-invasive surgery that reduces trauma associated with open surgery. The company has a market cap of $59.26 billion.
Inogen’s direct-to-customer business model has helped it gain a leading position in the oxygen therapy market. The company has a market cap of $4.85 billion.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Masimo Corporation (MASI - Free Report) recently announced that its SET Measure-through Motion and Low Perfusion pulse oximetry might be a useful initial screening method to identify children with Down Syndrome (DS) who are at a high risk of obstructive sleep apnea (OSA).
Out of 161 children with DS, 25 were separately diagnosed with OSA having monitored overnight using Masimo Radical-7 Pulse CO-Oximeters.
Notably, the screening method might replace multichannel sleep studies, which are expensive and also available at specialist centers.
For investors’ notice, in the recently-reported second quarter of 2018, Masimo shipped a whopping 58,700 oximeters and brain function monitors, which drove overall earnings.
Global Prospects
Per research by MarketsandMarkets, the sleep apnea devices market is projected to reach a worth of $6.49 billion by 2023 from an estimated $4.44 billion in 2018, at a CAGR of 7.8%. Increase in the incidence of lifestyle diseases like obesity and government efforts to spread awareness regarding sleep apnea propel growth.
Hence the latest development has been a well-timed one for Masimo.
Sleep Apnea in US
A research by the U.S. National Library of Medicine shows that OSA is a frequent occurrence during childhood, with a median incidence of about 10% among preschool and school-aged children.
MedTech bigwig ResMed Inc. (RMD - Free Report) is one of the key players in the sleep apnea devices market. The company offers devices like AirSense 10 Elite, AirSense 10 AutoSet and AirCurve 10 CS PaceWave which deserve a special mention here.
Meanwhile, the Zacks Consensus Estimate for the company’s current-year earnings is pegged at $2.90, reflecting growth of 18.4% from last year.
We believe developments such as these will help Masimo survive cutthroat competition from bigwigs like Intuitive Surgical (ISRG - Free Report) and Inogen, Inc. (INGN - Free Report) . Intuitive Surgical’s robot-based da Vinci surgical system enables minimally-invasive surgery that reduces trauma associated with open surgery. The company has a market cap of $59.26 billion.
Inogen’s direct-to-customer business model has helped it gain a leading position in the oxygen therapy market. The company has a market cap of $4.85 billion.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ISRG - FREE
Get the latest research report on RMD - FREE
Get the latest research report on MASI - FREE
Get the latest research report on INGN - FREE